Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema

被引:8
作者
Abdel-Hay, Ahmed [1 ,2 ]
Sivaprasad, Sobha [3 ]
Subramanian, Ahalya [1 ]
Barbur, John L. [1 ]
机构
[1] City Univ London, Appl Vis Res Ctr, London, England
[2] Musgrove Pk Hosp, Taunton, Somerset, England
[3] Moorfields Eye Hosp, London, England
来源
PLOS ONE | 2018年 / 13卷 / 06期
关键词
CHROMATIC SENSITIVITY; NEURAL APOPTOSIS; CLASSIFICATION; TRIAMCINOLONE; RETINOPATHY; PREVALENCE; PATHWAYS; HYPOXIA; SYSTEM;
D O I
10.1371/journal.pone.0199693
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose To evaluate changes in colour vision following intravitreal injection of Dexamethasone implant (Ozurdex) in patients with diabetic macular oedema (DMO). Both red-green (RG) and yellow-blue (YB) chromatic sensitivity were assessed using the Colour Assessment & Diagnosis (CAD) test which isolates the use of colour signals and provides age-corrected, statistical limits for normal trichromats. To determine whether colour changes and visual acuity (VA) post-treatment relate to central sub-field retinal thickness (CST). Methods Fourteen patients with DMO who were undergoing treatment with Ozurdex were recruited for this study. RG and YB colour thresholds were measured using the CAD test, best corrected visual acuity was assessed using the ETDRS chart and CST was measured using spectral domain optical coherence tomography (SD-OCT). All tests were performed monocularly at baseline and 24 weeks post injection. Results All patients (n = 14 eyes), had significant loss of RG and YB chromatic sensitivity at baseline (p<0.05). The mean age was 56 +/- 9.5 years. The age specific, monocular, upper normal limits for a 56 year old subject are 2.66 for RG and 2.85 for YB. In this study, the measured, pre injection thresholds (mean +/- SD) were 22.6 +/- 11.3 for RG and 16.2 +/- 3.76 for YB. There was significant improvement in RG threshold post injection (i.e., 19.2 +/- 10.8 (p<0.05)). No significant changes were found in the YB thresholds with corresponding mean and range values of: 15.8 +/- 4.6 (p = 0.23). CST pre-treatment was 542 +/- 135 mu m. After treatment and by week 24 the CST values decreased to 435 +/- 127 mu m. Conclusions RG colour thresholds provide a sensitive measure of functional change in diabetic subjects with macular oedema. The YB system is damaged severely in the DMO patients studied and shows little or no recovery post treatment. The improvement in VA and particularly in RG colour vision correlate well with the measured decrease in CST. The results suggest that the improvement in the RG chromatic sensitivity can provide a useful biomarker for monitoring the efficacy of treatment in DMO.
引用
收藏
页数:14
相关论文
共 39 条
  • [31] Loss of chromatic sensitivity in AMD and diabetes: a comparative study
    O'Neill-Biba, M.
    Sivaprasad, S.
    Rodriguez-Carmona, M.
    Wolf, J. E.
    Barbur, J. L.
    [J]. OPHTHALMIC AND PHYSIOLOGICAL OPTICS, 2010, 30 (05) : 705 - 716
  • [32] The prevalence of cataract in a population with and without type 2 diabetes mellitus
    Olafsdottir, Eydis
    Andersson, Dan K. G.
    Stefansson, Einar
    [J]. ACTA OPHTHALMOLOGICA, 2012, 90 (04) : 334 - 340
  • [33] PHOTOCOAGULATION FOR DIABETIC MACULAR EDEMA - EARLY TREATMENT DIABETIC-RETINOPATHY STUDY REPORT 1. EARLY TREATMENT DIABETIC RETINOPATHY STUDY RESEARCH GROUP
    PATZ, A
    RICE, TA
    MURPHY, RP
    NEWSOME, DA
    SHERMAN, SH
    FINE, SL
    AIELLO, LM
    RAND, LI
    BRIONES, JC
    SHAH, ST
    MYERS, FL
    BRESNICK, GH
    DAVIS, MD
    CHANDRA, SR
    WALLOW, IHL
    STEVENS, TS
    KLEIN, R
    FLYNN, HW
    BLANKENSHIP, GW
    KNOBLOCH, WH
    RAMSAY, RC
    CANTRILL, HL
    HODGKINSON, BJ
    RYAN, SJ
    LIANG, JC
    THOMAS, EL
    KLEIN, ML
    HANDELMAN, IL
    SIPPERLEY, JO
    CHENOWETH, RG
    ERNEST, JT
    LIANG, JC
    CUNHA-VAZ, J
    GOLDBERG, MF
    LINDBERG, CR
    VYGANTAS, C
    KLEIN, HJ
    BLAIR, N
    REDNAM, K
    KOPELOW, SM
    SHABO, AL
    STRAATSMA, BR
    BRIONES, JC
    KASSOFF, A
    LITTLE, HL
    JACK, RL
    CAVENDER, JC
    AI, E
    SORENSON, RL
    TASMAN, WS
    [J]. ARCHIVES OF OPHTHALMOLOGY, 1985, 103 (12) : 1796 - 1806
  • [34] Ranibizumab for Diabetic Macular Edema Results from 2 Phase III Randomized Trials: RISE and RIDE
    Quan Dong Nguyen
    Brown, David M.
    Marcus, Dennis M.
    Boyer, David S.
    Patel, Sunil
    Feiner, Leonard
    Gibson, Andrea
    Sy, Judy
    Rundle, Amy Chen
    Hopkins, J. Jill
    Rubio, Roman G.
    Ehrlich, Jason S.
    [J]. OPHTHALMOLOGY, 2012, 119 (04) : 789 - 801
  • [35] COLOR-VISION IN LONG-STANDING DIABETES-MELLITUS
    ROY, MS
    MCCULLOCH, C
    HANNA, AK
    MORTIMER, C
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 1984, 68 (03) : 215 - 217
  • [36] Seigel G, 2000, MOL VIS, V6, P157
  • [37] FURTHER STUDIES ON ACQUIRED DEFICIENCY OF COLOR DISCRIMINATION
    VERRIEST, G
    [J]. JOURNAL OF THE OPTICAL SOCIETY OF AMERICA, 1963, 53 (01) : 185 - &
  • [38] WINN B, 1994, INVEST OPHTH VIS SCI, V35, P1132
  • [39] Global Prevalence and Major Risk Factors of Diabetic Retinopathy
    Yau, Joanne W. Y.
    Rogers, Sophie L.
    Kawasaki, Ryo
    Lamoureux, Ecosse L.
    Kowalski, Jonathan W.
    Bek, Toke
    Chen, Shih-Jen
    Dekker, Jacqueline M.
    Fletcher, Astrid
    Grauslund, Jakob
    Haffner, Steven
    Hamman, Richard F.
    Ikram, M. Kamran
    Kayama, Takamasa
    Klein, Barbara E. K.
    Klein, Ronald
    Krishnaiah, Sannapaneni
    Mayurasakorn, Korapat
    O'Hare, Joseph P.
    Orchard, Trevor J.
    Porta, Massimo
    Rema, Mohan
    Roy, Monique S.
    Sharma, Tarun
    Shaw, Jonathan
    Taylor, Hugh
    Tielsch, James M.
    Varma, Rohit
    Wang, Jie Jin
    Wang, Ningli
    West, Sheila
    Xu, Liang
    Yasuda, Miho
    Zhang, Xinzhi
    Mitchell, Paul
    Wong, Tien Y.
    [J]. DIABETES CARE, 2012, 35 (03) : 556 - 564